<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2503245096
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AFUNDAS-L 50 MG 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CASPOFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        675.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AFUNDAS-L contains a medicine called caspofungin. This belongs to a group of medicines called anti-fungals.</p><p>&nbsp;</p><p>What AFUNDAS-L is used for</p><p>AFUNDAS-L is used to treat the following infections in children, adolescents and adults:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious fungal infections in your tissues or organs (called &lsquo;invasive candidiasis&rsquo;). This infection is caused by fungal (yeast) cells called Candida. People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections in your nose, nasal sinuses or lungs (called &lsquo;invasive aspergillosis&rsquo;) if other anti-fungal treatments have not worked or have caused side effects. This infection is caused by a mould called Aspergillus. People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suspected fungal infections if you have a fever and a low white cell count that have not improved on treatment with an antibiotic. People who are at risk of getting a fungal infection include those who have just had an operation or those whose immune systems are weak.</p><p>&nbsp;</p><p>How AFUNDAS-L works</p><p>AFUNDAS-L<strong> </strong>makes fungal cells fragile and stops the fungus from growing properly. This stops the infection from spreading and gives the body&#39;s natural defences a chance to completely get rid of the infection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use AFUNDAS-L</p><p>&bull; If you are allergic to caspofungin or any of the other ingredients of AFUNDAS-L (listed in section 6).</p><p>&nbsp;</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before you are given your medicine.</p><p>&nbsp;</p><p>b. Take special care with AFUNDAS-L</p><p>Talk to your doctor nurse or pharmacist before you are given AFUNDAS-L if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to any other medicines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had liver problems, you might need a different dose of this medicine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are already taking cyclosporine (used to help prevent organ transplant rejection or to suppress your immune system) as your doctor may need to run extra blood tests during your treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any other medical problem.</p><p>&nbsp;</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given AFUNDAS-L.</p><p>&nbsp;</p><p>AFUNDAS-L may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).</p><p>&nbsp;</p><p>c. Taking/using other medicines</p><p>Please tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because AFUNDAS-L can affect the way some other medicines work. Also some other medicines can affect the way AFUNDAS-L works.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine or tacrolimus (used to help prevent organ transplant rejection or to suppress your immune system) as your doctor may need to run extra blood tests during your treatment&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some HIV medicines such as efavirenz or nevirapine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin or carbamazepine (used for the treatment of seizures)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone (a steroid)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (an antibiotic)</p><p>&nbsp;</p><p><em>If any of the above apply to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given AFUNDAS-L. </em></p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Using AFUNDAS-L with food and drink </strong></p><p>Since the drug is applied intravenously, it is not affected by food and drink.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy &amp; Breast-feeding </strong></p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>Ask your doctor for advice before taking any medicine, if you are pregnant or breast-feeding or think you are pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AFUNDAS-L has not been studied in pregnant women. It should be used in pregnancy only if the potential benefit justifies the potential risk to the unborn baby.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women given AFUNDAS-L should not breast-feed.</p><p><em>&nbsp;</em></p><p><em>Ask your doctor or pharmacist for advice before taking any medicine. </em></p><p>&nbsp;</p><p>f. Driving and using machines</p><p>There is no information to suggest that AFUNDAS-L affects your ability to drive or operate machinery.</p><p>&nbsp;</p><p>g. Important information about some of the ingredients in AFUNDAS-L</p><p>AFUNDAS-L contains sucrose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor, nurse or pharmacist before you are given this medicine.&nbsp;</p><p>AFUNDAS-L contains mannitol. However, no side effects are to be expected due to the method of administration.</p><p>Each vial contains less than 1 mmol (23 mg) sodium. No side effects are to be expected in this dose for sodium.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use AFUNDAS-L exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure.</em><strong> </strong></p><p>&nbsp;</p><p><strong>Instructions for proper use and dose/frequency of administration:</strong></p><p>AFUNDAS-L will always be prepared and given to you by a healthcare professional.&nbsp; You will be given AFUNDAS-L:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once each day</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by slow injection into a vein (intravenous infusion)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; over about 1 hour.</p><p>&nbsp;</p><p>Your doctor will determine the duration of your treatment and how much Cancidas you will be given each day. Your doctor will monitor how well the medicine works for you. If you weigh more than 80 kg, you may need a different dose.</p><p>&nbsp;</p><p>Children and adolescents</p><p>The dose for children and adolescents may differ from the adult dose.</p><p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp; </strong><strong>If you use more AFUNDAS-L than you should:</strong></p><p>Your doctor will decide how much AFUNDAS-L you need and for how long each day. If you are worried that you may have been given too much AFUNDAS-L, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.&nbsp;</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp; </strong><strong>If you forget to use AFUNDAS-L: </strong></p><p><em>Do not take a double dose to make up for the forgotten doses. </em></p><p><em>&nbsp;</em></p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using AFUNDAS-L: </strong></p><p>Effects that may occur when treatment with AFUNDAS-L is stopped are not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Serious side effects:</strong></p><p><strong>Tell your doctor or nurse straight away if you notice any of the following side effects &ndash; you may need urgent medical treatment:&nbsp; </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching, feeling warm, swelling of your face, lips or throat or difficulty breathing &ndash; you may be having a histamine reaction to the medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing with wheezing or a rash that gets worse &ndash; you may be having an allergic reaction to the medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough, serious breathing difficulties &ndash; if you are an adult and have invasive aspergillosis you may be experiencing a serious respiratory problem that could result in respiratory failure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, skin peeling, mucous membrane sores, hives, large areas of peeling skin.<strong> </strong></p><p><strong>&nbsp;</strong></p><p>As with any prescription medicine, some side effects may be serious. Ask your doctor for more information.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong>Possible side effects</p><p><em>Like all medicines, AFUNDAS-L can cause side effects, although not everybody gets them. </em></p><p>&nbsp;</p><p>Other side effects in adults include&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased haemoglobin (decreased oxygen carrying substance in the blood), decreased white blood cells&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood albumin (a type of protein) in your blood, decreased potassium or low potassium levels in the blood&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vein&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea or vomiting&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including increased values of some liver tests)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash, skin redness or sweating more than usual&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills, fever&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching at the injection site.&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100 people: &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including disease of blood clotting, platelets, red blood cells and white blood cells)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar level in the blood, low calcium level in the blood, increase calcium level in the blood, low magnesium level in the blood, increase in acid level in the blood&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorientation, feeling nervous, being unable to sleep&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy, decreased feeling or sensitivity (especially in the skin), shaking, feeling sleepy, change in the way things taste, tingling or numbness&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision, increase in tears, swollen eyelid, yellowing of the whites of the eyes&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of fast or irregular heart beats, rapid heart beat, irregular heart beat, abnormal heart rhythm, heart failure&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, hot flush, high blood pressure, low blood pressure, redness along a vein which is extremely tender when touched&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tightening of the bands of muscle around the airways resulting in wheezing or coughing, fast breathing rate, shortness of breath that wakes you up, shortage of oxygen in the blood, abnormal breath sounds, crackling sounds in the lungs, wheezing, nasal congestion, cough, throat pain&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the belly&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, liver injury caused by a drug or chemical, liver disorder&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal skin tissue, generalised itching, hives, rash of varying appearance, abnormal skin, red often itchy spots on your arms and legs and sometimes on the face and the rest of the body&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of kidney function, sudden loss of kidney function&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Catheter site pain, injection site complaints (redness, hard lump, pain, swelling, irritation, rash, hives, leaking of fluid from the catheter into the tissue), inflammation of vein at injection site&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure and alterations in some laboratory blood tests (including kidney electrolyte and clotting tests), increased levels of the medicines you are taking that weaken the immune system&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort, chest pain, feeling of body temperature change, generally feeling unwell, general pain, swelling of the face, swelling of the ankles, hands or feet, swelling, tenderness, feeling tired.&nbsp;</p><p>&nbsp;</p><p>Side effects in children and adolescents &nbsp;</p><p><strong>Very common: </strong>may affect more than 1 in 10 people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever&nbsp;</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing, low blood pressure&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (increased values of some liver tests)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Catheter site pain&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests.&nbsp;</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist. </em></p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Keep AFUNDAS-L out of the reach and sight of children and store in its package.&nbsp; </em></p><p><strong>&nbsp;</strong></p><p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>&nbsp;</p><p>Once AFUNDAS-L has been prepared, it should be used straight away. This is because it does not contain any ingredients to stop the growth of bacteria. Only a trained healthcare professional who has read the complete directions should prepare the medicine (please see below &ldquo;Instructions of how to reconstitute and dilute AFUNDAS-L&rdquo;).</p><p>&nbsp;</p><p><em>Do not use AFUNDAS-L after the expiry date which is stated on the carton and the vial (the first two numbers are the month; the next four numbers are the year). The expiry date refers to the last day of that month.<strong> </strong></em></p><p>&nbsp;</p><p><em>Do not use AFUNDAS-L if you notice any defect in the product and/or on its packaging. </em></p><p><em>&nbsp;</em></p><p><em>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. </em></p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is caspofungin. Each vial of AFUNDAS-L contains 50 mg Caspofungin (as acetate salt)&nbsp;</p><p>The other ingredients are sucrose, mannitol, succinic acid, sodium hydroxide (please see section 3 Before you use AFUNDAS-L)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                AFUNDAS-L is a sterile, white or almost white lyophilized mass in colorless glass vial with rubber closure and flip-off aluminum cap. 
 
Each pack contains one vial of powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Gensenta İla&ccedil; Sanayi ve Ticaret A.Ş. İş Kuleleri, Levent Mah., Meltem Sok.&nbsp; No: 10 Kule: 2 Kat: 24&nbsp; 4. Levent, Beşiktaş, İstanbul/TURKEY&nbsp; Tel: +90 212 337 38 00&nbsp; Fax: +90 212 337 38 01&nbsp;</p><p>e-mail: info@gensenta.com.tr</p><p>&nbsp;</p><p><strong>Manufacturer: </strong>&nbsp;</p><p>Gensenta İla&ccedil; Sanayi ve Ticaret A.Ş. Sanayi Cad. No: 13&nbsp;</p><p>Yenibosna &ndash; Bah&ccedil;elievler - Istanbul&nbsp;</p><p>TURKEY&nbsp;</p><p>&nbsp;</p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder: </em>&nbsp;Kingdom of Saudi Arabia&nbsp; Salehiya Trading Est.&nbsp;</p><p>P.O. Box: 991 Riyadh: 11421&nbsp; Tel. No.: +966 11 464 6955&nbsp;</p><p>Fax No.: +966 11 463 4362&nbsp;</p><p>Website: www.salehiya.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 01/2021; version number 05 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو أفنداس-إل</strong></p><p dir="RTL">يحتوي أفنداس-إل على دواء يسمى كاسبوفنجين.&nbsp;</p><p dir="RTL">و هو ينتمي إلى مجموعة أدوية تدعى مضاداّت الفطريات.</p><p dir="RTL">ما هي استخدامات أفنداس-إل<strong> </strong></p><p dir="RTL">يستخدم أفنداس-إل لعلاج الإلتهابات التالية عند الأطفال والمراهقين والبالغين:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهابات فطرية خطيرة في أنس جتك&nbsp; أو&nbsp; أعضاءك )تسمى &quot;داء المبيضات الغازية.(&quot; تتسبب الخلايا الفطرية )الخميرة( المسماة كانديدا بهذا الإلتهاب. يتضمن حصول هذا النوع من الإلتهاب لدى الأشخاص الذين خضعوا لعملية مؤخر ا&nbsp; أو أولئك الذين لديهم أجهزة مناعة ضعيفة. الحمى والقشعريرة التي لا تستجيب للمضادات الحيوية هي أكثر العلامات شيوعا&nbsp;&nbsp; لهذا النوع من الإلتهاب.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهابات فطرية في أنفك أو الجيوب الأنفية أو الرئتين )تسمى &rsquo; داء الرشاشيات الغزوية&lsquo;( إذا لم يكن العلاج بمضادات الفطريات الأخرى فعالا&nbsp; أو تسببت بحدوث أعراض جانبية. يحدث هذا الإلتهاب بسبب عفن يسمى الرشاشيات. يتضمن حصول هذا النوع من الإلتهاب لدى الأشخاص الذين يتناولون العلاج الكيميائي و أولئك الذين قاموا بزراعة أعضاء و أولئك الذين لديهم أجهزة مناعية ضعيفة .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهابات فطرية مشتبه بها إذا كان لديك حمّى و انخفاض في عدد خلايا الدم البيضاء و التي لم تتحسن مع العلاج بالمضادات الحيوية. يتضمن الأشخاص المعرضون لخطر الإصابة بإلتهاب فطري أولئك الذي تعرضوا لعملية مؤخرا&nbsp; أو أولئك الذين لديهم أجهزة مناعة ضعيفة.</p><p dir="RTL"><strong>كيفية عمل أفنداس-إل</strong></p><p dir="RTL">يقوم أفنداس-إل بجعل الخلايا الفطرية ضعيفة و تمنع الفطريات من النمو بشكل صحيح. و هذا يمنع الإلتهاب من الإنتشار و إعطاء فرصة للمقاومة الطبيعية للجسم للتخلص من الإلتهاب بشكل كامل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ .لا تستخدم أفنداس-إل </strong></p><p dir="RTL">&bull; اذا كانت لديك حساسية من كاسبوفنجين او اي مكون آخر لـ أفنداس-إل )مدرجة في البند 6(.</p><p dir="RTL">إذا لم تكن متأكدا ، تحدث إلى طبيك أو الممرضة أو الصيدلي قبل إعطائك دواءك.</p><p dir="RTL"><strong>ب .تعامل مع أفنداس-إل بعناية خاصة </strong></p><p dir="RTL">تحدث الى طبيبك، الممرضة أو الصيدلي قبل اعطائك أفنداس-إل اذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية لأي أدوية الأخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك في أي وقت مشاكل في الكبد، قد تحتاج الى جرعة مختلفة من هذا الدواء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تأخذ سايكلوسبورين في ذلك الحين )والذي يستخدم للمساعدة في الحول دو ن رف ض الأعضاء المزروعة أو تثبيط جهازك المناعي( فقد يحتاج طبيبك لاجراء فحوصات دم اضافية خلال فترة العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل طبية أخرى</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك )أو لم تكن متأكدا(، تحدث إلى طبيبك أو الممرضة أو الصيدلي قبل إعطائك أفنداس-إل.&nbsp;</p><p dir="RTL">قد يتسبب أفنداس-إل أيضا بآثار جانبية جلدية خطرة مثل متلازمة ستيفنز-جونسون (SJS) و تقشر الأنسجة المتموّتة البشروية التسممي) TEN (.&nbsp;</p><p dir="RTL"><strong>جـ .أخذ/استخدام أدوية أخرى&nbsp; </strong></p><p dir="RTL">الرجاء إخبار طبيبك أو الممرضة أو الصيدلي إذا كنت تتناول&nbsp; أو تناولت مؤخرا&nbsp; أو قد تتناول أي دواء آخر. هذا يشمل الأدوية التي يتم الحصول عليها بدون وصفة طبية، كما يشمل الأدوية العشبية. و هذا لأنّ أفنداس-إل يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. و أيضا من الممكن أن تؤثر بعض الأدوية الأخرى على طريقة عمل أفندا س-إل.</p><p dir="RTL">اخبر طبيبك، الممرضة أو الصيدلي اذا كنت تأخذ اي من الادوية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سايكلوسبورين أو تاكروليمس )يستخدم للمساعدة في الحول دون رفض الأعضاء المزروع ة أو تثبيط جهازك المناعي( قد يحتاج طبيبك لإجراء فحوصات دم إضافية أثناء فترة علاجك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية نقص المناعة المكتسبة مثل إفاڤيرينز او نيڤيرابين&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين أو كاربامازابين )تستخدم لعلاج نوبات الصرع(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكساميثازون )ستيرويد(&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين )مضاد حيوي(&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك )أو إن لم تكن متأكدا( ،استشر طبيبك أو الممرضة أو ا لصيدلي قبل إعطائك أفنداس-إل. <em>&nbsp;</em></p><p dir="RTL"><strong>د .استخدام أفنداس-إل مع الطعام&nbsp; أو الشراب</strong></p><p dir="RTL">حيث أن الدواء يؤخذ عن طريق الوريد، فإنه لا يتأثر بالطعام او الشراب.</p><p dir="RTL"><strong>هـ .الحمل والرضاع ة الحمل</strong><strong> و الرضاعة </strong></p><p dir="RTL">اسألي طبيبك لأخذ المشورة قبل تناولك لأي دواء، إذا كنتِ حامل&nbsp; أو مرضعة أو تتوقعين أنكّ حامل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يتم دراسة أفنداس-إل لدى النساء الحوامل. ينبغي استخدامه في الحمل فقط إذا كانت الفائدة المحتملة تبرر المخاطر المحتملة على الجنين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على النساء عدم الإرضاع إذا تم إعطاؤهم أفنداس-إل.&nbsp;</p><p dir="RTL">اسألي طبيبك أو الصيدلي من أجل النصيحة قبل تناولك لأي دواء.<em> </em></p><p dir="RTL"><strong>&zwnj;و</strong><strong>.القيادة واستخدام الآلات </strong></p><p dir="RTL">لا توجد معلومات تشير إلى أن أفنداس-إل يؤثر على قدرتك على القيادة أو تشغيل الآلات .</p><p dir="RTL"><strong>&zwnj;ز</strong><strong>.معلومات مهمة بشأن بعض مكونات أفنداس-إل </strong>&nbsp;</p><p dir="RTL">أفنداس-إل يحتوي على سكروز )نوع من أنواع السكريات(. إذا تم إخبارك من قبل طبيبك أنك لا تستطيع تحمل أو هضم بعض السكريات، فقم باعلام طبيبك، الممرضة أو الصيدلي قبل تناول هذا الدواء.&nbsp;</p><p dir="RTL">أفنداس-إل يحتوي على مانيتول .ومع ذلك، لا توجد اعراض جانبية متوقعة بسبب طريقة الاستخدام&nbsp;</p><p dir="RTL">كل قارورة تحتوي على أقل م ن 1 مل مول) 23ملغم( صوديوم .لا توجد أعراض جانبية متوقعة لهذه الجرعة من الصوديوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استخدم أفنداس-إل دائما كما اخبرك طبيبك&nbsp; تماما أو&nbsp; مقدم الرعاية الصحية .يجب مراجعة طبيبك، مقدم الرعاية الصحية أو الصيدلي إن كنت غير متأكد .<em> </em></p><p dir="RTL"><strong>تعليمات الاستخدام الصحيح والجرعة / تكرار الاستخدام: </strong></p><p dir="RTL">سيتم تحضير أفنداس-إل دائما ويعطى لك من قبِل أخصائي العناية الصحية.</p><p dir="RTL">سيتم إعطاؤك أفنداس-إل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرّة واحدة كل يوم&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; عن طريق الحقن البطيء في الوريد) التشريب الوريدي(&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على مدى فترة تصل إلى ساعة.&nbsp;</p><p dir="RTL">سيقوم طبيبك بتحديد مدة علاجك و كمية أفنداس-إل التي سيتم إعطاؤك إياها يوميا . سيقوم طبيبك بمراقبة مدى عمل الدواء بشكل جيد لك. إذا كان وزنك أكثر من 80 كغم، قد تحتاج لجرعة مختلفة.</p><p dir="RTL"><strong>الأطفال و المراهقين&nbsp; </strong></p><p dir="RTL">قد تختلف جرعة الأطفال و المراهقين عن جرعة البالغين. <strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا استخدمت أفنداس-إل أكثر من اللازم: </strong></p><p dir="RTL">سيقرر طبيبك كم تحتاج من أفنداس-إل و إلى أي كل يوم. إذا كنت قلقا&nbsp; من أنه تم إعطاؤك كمية اكثر من اللازم من أفنداس- إل، أخبر طبيبك أو الممرض فورا .</p><p dir="RTL">إذا كان لديك أي أستفسارات أخرى عن استعمال هذا الدواء، استشر طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL"><strong>ب&zwnj;.&nbsp; </strong><strong>إذا نسيت ان تستخدم أفنداس -إل: </strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعات التي نسيتها.<em> </em></p><p dir="RTL"><strong>ج .إذا توقفت عن استخدام أفنداس-إل: </strong></p><p dir="RTL">الآثار التي قد تحدث عند ايقاف العلاج باستخدام أفنداس-إل غير معروفة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>. أعراض جانبية خطيرة&nbsp; </strong></p><p dir="RTL"><strong>أخبر طبيبك أو الممرضة على الفور إذا لاحظت أي من الأعراض الجانبية التالية - قد تحتاج إلى علاج طبي عاجل</strong><strong>:</strong><strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة، شعور بالدفء، تورم في وجهك أو الشفاه أو الحلق أو صعوبة في التنفس- قد يكون لديك ردة فعل هيستامينية للدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مع صفير أو طفح جلدي والذي يزداد سوءا &ndash; قد يكون لديك ردة فعل تحسسية للدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال، صعوبات&nbsp; خطيرة في التنفس &ndash; إذا كنت&nbsp; بالغا و لديك داء الرشاشيات الغزوية قد تكون تعاني من مشاكل تنفسية خطرة والتي قد تؤدي إلى فشل في الجهاز التنفسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، تقشير في الجلد، تقرحات في الأغشية المخاطية، شرى، مناطق واسعة من الجلد المتقشر.</p><p dir="RTL">كما هو الحال مع أي دواء بوصفة طبية، بعض الأعراض الجانبية قد تكون خطيرة. اسأل طبيبك للحصول على مزيد من المعلومات<strong>. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>. أعراض جانبية محتملة </strong></p><p dir="RTL">كجميع<em> </em>الادوية،<em> </em>قد<em> </em>يسبب<em> </em>أفنداس<em>-</em>إل<em> </em>أعراض<em> </em>جانبية<em> </em>ولكن<em> </em>قد<em> </em>لا<em> </em>تحصل<em> </em>عند<em> </em>الجميع<em>.</em><em> </em></p><p dir="RTL">تشمل الأعراض الجانبية الأخرى عند البالغين <strong>شائع :</strong>قد تؤثر على ما يصل الى 1 من 10 أشخاص: <strong>&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الهيموجلوبين )إنخفاض&nbsp; المادة التي تحمل الأكسجين في الدم(، انخفاض كريات الدم البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ألبومين الدم&nbsp; )نوع من البروتين( في دمك، انخفاض البوتاسيو م أو انخفاض مستوى البوتاسيوم في الدم &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدا ع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الوري د</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنف س</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسهال أو غثيان أو قي ء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في بعض فحوصات الدم المخبرية&nbsp; )زيادة في قيم بعض فحوصات الكبد (</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أ و طفح جلدي أ و إحمرار في الجلد أو تعر ق أكثر من المعتاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المفاص ل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، حم ى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في مكان الحقن</p><p dir="RTL"><strong>غير شائع :</strong>قد تؤثر على ما يصل الى 1 من 100 شخص:<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في بعض فحوصات الدم المخبرية&nbsp; )تشمل مرض تخثر الدم، الصفائح الدموية، كريات الدم الحمرا ء و كريات الدم البيضاء( &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، زياد ة ف ي كمية سوائل الجسم، عدم تواز ن الأملاح في الجسم، ارتفاع مستوى السكر في الدم، انخفاض مستوى الكالسيوم في الدم، زيادة مستوى الكالسيوم في الدم، انخفاض مستوى المغنيسيوم في الدم، زيادة في مستوى الحمض في الد م</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارتباك، الشعور بالتوتر، عدم القدرة على النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار، تناقص الإحساس أو التحسس) خاصة في الجلد(، ارتعاش، الشعور بالنعاس، تغير في مذاق الأشياء، وخز أو تنمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، زيادة في الدموع، تورم الجفن، اصفرار بياض العينين &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بتسارع أو عدم انتظام دقات القلب، تسارع دقات القلب، عدم انتظام دقات القلب، ايقاع غير طبيعي للقلب ، قصور القل ب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحمرار، وهجان، ارتفاع ضغط الدم، انخفاض ضغط الدم، إحمرار عل ى طول الوريد و الذي يكون حساسا جد ا&nbsp; عند لمس ه</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضيق أشرطة العضلات حول مجرى الهواء مما يؤدي إلى صفير او سعال، زيادة في معدل التنفس، ضيق في التنفس بحيث يوقظك ليلا، نقص&nbsp; الأكسجين في الدم، أصوات تنفس غير طبيعية، أصوات طقطقة في الرئتان، صفير ، احتقان الأنف، سعال، ألم&nbsp; في الحلق &bull; ألم في البطن، ألم في المنطقة العلوية من البطن، انتفاخ، إمساك، صعوبة في البلع، جفاف الفم، عسر في الهضم، مرور الغازات، ضيق في المعدة، تور م نتيجة لتزايد السوائل حو ل البط ن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تدفق المادة الصفراء، تضخم الكبد، اصفرا ر ف ي الجل د&nbsp; و/أ و بياض العينين، ضرر ف ي الكبد ناتج عن دواء أو مادة كيميائية، اضطرابات في الكب د</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنسجة جلد غير طبيعية، حكة عامة، شرى، طفح جلدي بمظاهر مختلفة، جلد غير طبيعي، بقع حمراء عادة ذات حكة على ذراعيك و ساقيك و في بعض الأحيان على الوج ه و سائر الجس م</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر، ألم في الذراع أو الساق، ألم في العظام، ألم ف ي العضلات، ضعف ف ي العضلا ت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان وظيفة الكلى، فقدان فجائي لوظيفة الكل ى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة القسطرة، شكاوي ف ي مكان الحقن )إحمرار، كتل ة قاسية، ألم، تورم، تهيج، طفح جلدي، شرى، تسريب سوائل من القسطرة إل ى داخل النسيج(، إلتهاب الوريد في مكان الحق ن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع ضغط الدم و تغير في بعض فحوصات الدم المخبرية )تشمل فحوصات أملاح الكلى و فحوصات التخثر(، زيادة في مستويات الأدوية التي تتناولها و الذي يضع ف جهاز المناع ة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في منطقة الصدر، ألم في الصدر، شعور بتغير في درجة حرارة الجسم، شعور عام بالتوعك، ألم عام، تورم في الوجه، تورم في الكاحل أو اليدين أو القدمين، تورم، إيلام، شعور بالتعب.</p><p dir="RTL"><strong>الأعراض الجانبية في الأطفال و المراهقين شائع جدا: </strong>قد يؤثر على أكثر من&nbsp; 1 لكل 10 أشخاص:<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL"><strong>شائع :</strong>قد يؤثر على ما يصل الى 1 من 10 أشخاص:<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدا ع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحمرار، انخفاض ضغط الد م</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في بعض فحوصات الد م المخبرية )زيادة في قيم بعض فحوصات الكبد(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلد ي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موقع القسطر ة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات&nbsp; في بعض فحوصات الدم المخبرية.</p><p dir="RTL">إذا<em> </em>أصبحت<em> </em>إحدى<em> </em>الأعراض<em> </em>الجانبية <em>&nbsp;</em>خطيرة،<em> </em>أو<em> </em>إذا<em> </em>لاحظت<em> </em>أي<em> </em>أعراض<em> </em>جانبية<em> </em>غير<em> </em>مذكورة <em>&nbsp;</em>في<em> </em>النشرة،<em> </em>يرجى<em> </em>اعلام<em> </em>طبيبك، مقدم<em> </em>الرعاية<em> </em>الصحية<em> </em>أو<em> </em>الصيدلي<em>.</em><em> </em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ<em> </em>أفنداس<em>-</em>إل<em> </em>بعيدا<em> </em>عن<em> </em>متناول<em> </em>و<em> </em>مرأى<em> </em>الأطفال<em> </em>و<em> </em>يحف ظ<em> </em>في<em> </em>علبته<em>.</em><em> </em></p><p dir="RTL">يحفظ في الثلاجة) 2 &deg; م إلى 8 &deg; م(&nbsp;</p><p dir="RTL">بمجرد تحضير أفنداس-إل، يجب استخدامه فورا . حيث أنه لا يحتوي على أي مكونات لوقف نمو البكتيريا. يجب أن يتم تحضير الدواء&nbsp; فقط من قبل أخصائي العناية الصحية والذي قد قرأ التعليمات كاملة )يرجى النظر في الأسفل&quot; &nbsp;تعليمات كيفية إعادة حل و تخفيف أفنداس-إل&quot;(.&nbsp;</p><p dir="RTL">لا تستخدم أفنداس-إل بعد تاريخ الإنتهاء الموجود على الكرتونة و القارورة )أول رقمان يدلان على الشهر؛ الأرقام الأربع التالية تدل على السنة(. يشير تاريخ الإنتهاء إلى آخر يوم&nbsp; قي ذلك الشهر.<em> </em></p><p dir="RTL">لا تستخدم أفنداس-إل إذا لاحظت أي عيب في المنتج و/أو عبوته.<em> </em></p><p dir="RTL">لا ينبغي التخلص من الأدوية&nbsp; في&nbsp; مياه&nbsp; الصرف الصحي أو النفايات المنزلية .اسأل الصيدلي عن كيفة التخلص من&nbsp; الأدوية التي لم تعد بحاجة لها .ستساعد هذه التدابير في الحفا ظ على البيئة .<em> </em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي كاسبوفنجين. كل قارورة من<strong><em> </em></strong>أفنداس-إل تحتوي على 50 ملغم كاسبوفنجين (كأملاح الاسيتيت)</p><p>المكونات الأخرى هي سكروز، مانيتول، حمض السكسينيك، هيدروكسيد الصوديوم (يرجى النظر للبند 3 قبل استعمالك أفنداس-إل)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong><em>ب. </em>كيف يبدو أفنداس-إل وماهي محتويات العلبة:</strong></p><p>أفنداس-إل هو كتلة &nbsp;معقّمة بيضاء أو مقاربة للبياض مجففة بالتجميد في قارورة زجاجية غير ملونة بسدادة مطاطية وغطاء فتح علوي من الألومنيوم.</p><p>تحتوي كل عبوة على قارورة واحدة من المسحوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp; حامل ترخيص التسويق : </strong></p><p dir="RTL">&nbsp;شركة جينسينتا الدوائية للصناعة و التجارة</p><p>İş Kuleleri, Levent Mah., Meltem Sok.</p><p>No: 10 Kule: 2 Kat: 24&nbsp;</p><p>4. Levent, Beşiktaş, İstanbul/TURKEY&nbsp;</p><p>Tel: +90 212 337 38 00&nbsp;</p><p>Fax: +90 212 337 38 01&nbsp;</p><p>e-mail: info@gensenta.com.tr</p><p><strong>المصنع</strong></p><p dir="RTL">شركة جينسينتا الدوائية للصناعة و التجارة 13Sanayi Cad. No: Yenibosna &ndash; Bah&ccedil;elievler &ndash; اسطنبول&nbsp;&nbsp; تركيا&nbsp;</p><p dir="RTL">لأي<em> </em>معلومات<em> </em>عن<em> </em>هذا<em> </em>المنتج<em> </em>الطبي،<em> </em>يرجى<em> </em>التواصل<em> </em>مع<em> </em>الوكيل<em> </em>المحلي<em> </em>لحامل<em> </em>ترخيص<em> </em>التسويق:<em> </em></p><p dir="RTL">المملكة العربية السعودية مؤسسة الصالحية التجاري ة</p><p>ص.ب .991&nbsp; الرياض: 11421 تليفون:966114646955+&nbsp; فاكس:966114634362+ موقع الكتروني: www.salehiya.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تاريخ لاعتماد هذه النشرة هو 01/2021 ؛ رقم الاصدار: 05 د 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AFUNDAS-L 50 mg Powder for Concentrate for Solution for Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains; Active substance: 
Caspofungin 	50 mg (as acetate salt) 
 
Excipients: 
Sucrose 	35.7 mg 
Mannitol 	23.8 mg 
Sodium Hydroxide  	q.s. pH 6.0 (to adjust the pH) 
 
For a full list of other excipients, see section 6.1. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Concentrate for Solution for Infusion  
Before reconstitution, the powder is a white to off-white compact, powder 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of invasive candidiasis in adult or paediatric patients.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.</p><p>Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caspofungin should be initiated by a physician experienced in the management of invasive fungal infections.</p><p><strong>&nbsp;</strong></p><p><strong>Posology: </strong></p><p><em>Adult patients </em></p><p>A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary based on gender or race (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric patients (12 months to 17 years) </em></p><p>In paediatric patients (12 months to 17 years of age), dosing should be based on the patient&#39;s body surface area (see Instructions for Use in Paediatric Patients, Mosteller<sup>1</sup> Formula). For all indications, a single 70-mg/m<sup>2</sup> loading dose (not to exceed an actual dose of 70 mg) should be administered on Day 1, followed by 50 mg/m<sup>2</sup> daily thereafter (not to exceed an actual dose of 70 mg daily). If the 50-mg/m<sup>2</sup> daily dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg/m2 daily (not to exceed an actual daily dose of 70 mg).</p><p>&nbsp;</p><p>The safety and efficacy of caspofungin have not been sufficiently studied in clinical trials involving neonates and infants below 12 months of age. Caution is advised when treating this age group.</p><p>Limited data suggest that caspofungin at 25 mg/m<sup>2</sup> daily in neonates and infants (less than 3 months of age) and 50 mg/m<sup>2</sup> daily in young children (3 to 11 months of age) can be considered (see section 5.2).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>Duration of empirical therapy should be based on the patient&#39;s clinical response. Therapy should be continued until up to 72 hours after resolution of neutropaenia (ANC&ge; 500). Patients found to have a fungal infection should be treated for a minimum of 14 days and treatment should continue for at least 7 days after both neutropaenia and clinical symptoms are resolved.</p><p>&nbsp;</p><p>Duration of treatment of invasive candidiasis should be based upon the patient&#39;s clinical and microbiological response. After signs and symptoms of invasive candidiasis have improved and cultures have become negative, a switch to oral antifungal therapy may be considered. In general, antifungal therapy should continue for at least 14 days after the last positive culture.</p><p>&nbsp;</p><p>Duration of treatment of invasive aspergillosis is determined on a case by case basis and should be based upon the severity of the patient&#39;s underlying disease, recovery from immunosuppression, and clinical response. In general, treatment should continue for at least 7 days after resolution of symptoms.</p><p>&nbsp;</p><p>The safety information on treatment durations longer than 4 weeks is limited. However, available data suggest that caspofungin continues to be well tolerated with longer courses of therapy (up to 162 days in adult patients and up to 87 days in paediatric patients).</p><p>&nbsp;</p><p><strong><em>Special populations </em></strong></p><p><strong>&nbsp;</strong></p><p>Elderly patients</p><p>In elderly patients (65 years of age or more), the area under the curve (AUC) is increased by approximately 30%. However, no systematic dosage adjustment is required. There is limited treatment experience in patients 65 years of age and older (see section 5.2).</p><p><em>&nbsp;</em></p><p><strong>Renal impairment </strong></p><p>No dosage adjustment is necessary based on renal impairment (see section 5.2)</p><p><strong>&nbsp;</strong></p><p>Hepatic impairment</p><p>For adult patients with mild hepatic impairment (Child-Pugh score 5 to 6), no dosage adjustment is needed. For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), caspofungin 35 mg daily is recommended based upon pharmacokinetic data. An initial 70 mg loading dose should be administered on Day-1. There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in pediatric patients with any degree of hepatic impairment (see section 4.4).</p><p><strong>&nbsp;</strong></p><p>Co-administration with inducers of metabolic enzymes</p><p>Limited data suggest that an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered when co-administering caspofungin in adult patients with certain inducers of metabolic enzymes (see section 4.5). When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with these same inducers of metabolic enzymes (see section 4.5), a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70 mg) should be considered.</p><p>&nbsp;</p><p><strong>Method of administration: </strong></p><p>After reconstitution and dilution, the solution should be administered by slow intravenous infusion over approximately 1 hour. For preparation instructions see section 6.6.&nbsp;</p><p>Both 70 mg and 50 mg vials are available.</p><p>Caspofungin should be given as a single daily infusion.</p><p>&nbsp;</p><p><sup>1</sup>Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17):1098</p><p>(letter)</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AFUNDAS-L is contraindicated in patients who have hypersensitivity to any of its ingredients. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anaphylaxis has been reported during administration of caspofungin. If this occurs, caspofungin should be discontinued and appropriate treatment administered. Possibly histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth, or bronchospasm have been reported and may require discontinuation and/or administration of appropriate treatment.</p><p>&nbsp;</p><p>Limited data suggest that less common non-<em>Candida</em> yeasts and non-<em>Aspergillus</em> molds are not covered by caspofungin. The efficacy of caspofungin against these fungal pathogens has not been established.&nbsp;</p><p>&nbsp;</p><p>Concomitant use of caspofungin with cyclosporine has been evaluated in healthy adult volunteers and in adult patients.&nbsp;</p><p>&nbsp;</p><p>Some healthy adult volunteers who received two 3 mg/kg doses of cyclosporine with caspofungin showed transient increases in alanine transaminase (ALT) and aspartate transaminase (AST) of less than or equal to 3-fold the upper limit of normal (ULN) that resolved with discontinuation of the treatment. In a retrospective study of 40 patients treated during marketed use with caspofungin and cyclosporine for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted. These data suggest that caspofungin can be used in patients receiving cyclosporine when the potential benefit outweighs the potential risk. Close monitoring of liver enzymes should be considered if caspofungin and cyclosporine are used concomitantly.&nbsp;</p><p>&nbsp;</p><p>In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20% and 75%, respectively. A reduction of the daily dose to 35 mg is recommended for adults with moderate hepatic impairment. There is no clinical experience in adults with severe hepatic impairment or in pediatric patients with any degree of hepatic impairment. A higher exposure than in moderate hepatic impairment is expected and caspofungin should be used with caution in these patients (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult and pediatric patients treated with caspofungin. In some adult and pediatric patients with serious underlying conditions who were receiving multiple concomitant medications with caspofungin, cases of clinically significant hepatic dysfunction, hepatitis and hepatic failure have been reported; a causal relationship to caspofungin has not been established. Patients who develop abnormal liver function tests during caspofungin therapy should be monitored for evidence of worsening hepatic function and the risk/benefit of continuing caspofungin therapy should be re-evaluated.</p><p>&nbsp;</p><p>Excipients&nbsp;</p><p>Sucrose: This medicinal product contains sucrose. Due to route of administration any warning is not necessary (see section 2). Patients with rare hereditary problems of fructose intolerance or sucroseisomaltase insufficiency should not take this medicinal product (see section 2).</p><p>&nbsp;</p><p>Mannitol: Due to route of administration any warning is not necessary.</p><p>Sodium: Sodium hydroxide q.s. is used for pH adjustment. Each vial of this medicinal product contains less than 1 mmol (23 mg) sodium; but at this dose is not expected to cause any side effects due to sodium.&nbsp;</p><p>&nbsp;</p><p>Cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported after post-marketing use of caspofungin. Caution should apply in patients with history of allergic skin reaction (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies <em>in vitro</em> show that caspofungin is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system. In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other substances. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes. However, caspofungin has been shown to interact with other medicinal products in pharmacological and clinical studies.</p><p>&nbsp;</p><p>In two clinical studies performed in healthy adult subjects, cyclosporine A (one 4 mg/kg dose or two 3 mg/kg doses 12 hours apart) increased the AUC of caspofungin by approximately 35%. These AUC increases are probably due to reduced uptake of caspofungin by the liver. Caspofungin did not increase the plasma levels of cyclosporine. There were transient increases in liver ALT and AST of less than or equal to 3-fold the upper limit of normal (ULN) when caspofungin and cyclosporine were co-administered, that resolved with discontinuation of the medicinal products. In a retrospective study of 40 patients treated during marketed use with caspofungin and cyclosporine for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted (see section 4.4). Close monitoring of liver enzymes should be considered if the two medicinal products are used concomitantly.</p><p>&nbsp;</p><p>Caspofungin reduced the trough concentration of tacrolimus by 26% in healthy adult volunteers. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.&nbsp;</p><p>&nbsp;</p><p>Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not altered to a clinically relevant extent by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus. Caspofungin did not influence the pharmacokinetics of amphotericin B, itraconazole, rifampicin or mycophenolate mofetil. Although safety data are limited it appears that no special precautions are needed when amphotericin B, itraconazole, nelfinavir or mycophenolate mofetil are co-administered with caspofungin.&nbsp;</p><p>&nbsp;</p><p>Rifampicin caused a 60% increase in AUC and 170% increase in trough concentration of caspofungin on the first day of co-administration when both medicinal products were initiated together in healthy adult volunteers. Caspofungin trough levels gradually decreased upon repeated administration. After two weeks&#39; administration rifampicin had limited effect on AUC, but trough levels were 30% lower than in adult subjects who received caspofungin alone. The mechanism of interaction could possibly be due to an initial inhibition and subsequent induction of transport proteins. A similar effect could be expected for other medicinal products that induce metabolic enzymes. Limited data from population pharmacokinetics studies indicate that concomitant use of caspofungin with the inducers efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin, or carbamazepine may result in a decrease in caspofungin AUC. When co-administering inducers of metabolic enzymes, an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered in adult patients (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>All adult drug-drug interaction studies described above were conducted at a 50 or 70 mg daily</u> caspofungin dose. The interaction of higher doses of caspofungin with other medicinal products has not been formally studied.</p><p>&nbsp;</p><p>In pediatric patients, results from regression analyses of pharmacokinetic data suggest that coadministration of dexamethasone with caspofungin may result in clinically meaningful reductions in caspofungin trough concentrations. This finding may indicate that pediatric patients will have similar reductions with inducers as seen in adults. When caspofungin is co-administered to pediatric patients (12 months to 17 years of age) with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70mg/m<sup>2</sup> daily (not to exceed an actual daily dose of 70 mg) should be considered.&nbsp;</p><p><strong><em>&nbsp;</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no or limited data from the use of caspofungin in pregnant women. Caspofungin should not be used during pregnancy unless clearly necessary. Animal studies have shown developmental toxicity (see section 5.3). Caspofungin has been shown to cross the placental barrier in animal studies.&nbsp;</p><p>&nbsp;</p><p>Lactation</p><p>It is unknown whether caspofungin is excreted in human milk. Available pharmacodynamic/ toxicological data in animals have shown excretion of caspofungin in milk. Women receiving caspofungin should not breast-feed.</p><p>&nbsp;</p><p>Fertility&nbsp;</p><p>For caspofungin, there were no effects on fertility in studies conducted in male and female rats (see section 5.3). There are no clinical data for caspofungin to assess its impact on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile: </strong></p><p>Hypersensitivity reactions (anaphylaxis and possibly histamine-mediated adverse reactions) have been reported (see section 4.4).</p><p>&nbsp;</p><p>Also reported in patients with invasive aspergillosis were pulmonary edema, adult respiratory distress syndrome (ARDS), and radiographic infiltrates.</p><p><strong>&nbsp;</strong></p><p>b. Tabulated summary of adverse reactions</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p>The following adverse reactions were reported:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Adult patients</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td colspan="2"><p>Common:</p></td><td style="vertical-align:top"><p>Hemoglobin decreased, hematocrit decreased, white blood cell count decreased</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anemia, thrombocytopenia, coagulopathy, leukopenia, eosinophil count increased, platelet count decreased, platelet count increased, lymphocyte count decreased, white blood cell count increased, neutrophil count decreased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypokalemia</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fluid overload, hypomagnesaemia, anorexia, electrolyte imbalance, hyperglycemia, hypocalcaemia, metabolic acidosis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anxiety, disorientation, insomnia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, dysgeusia, paresthesia, somnolence, tremor, hypoesthesia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Ocular icterus, vision blurred, eyelid edema, lacrimation increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Palpitations, tachycardia, arrhythmia, atrial fibrillation, cardiac failure congestive</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Phlebitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombophlebitis, flushing, hot flush, hypertension, hypotension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnea</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Nasal congestion, pharyngolaryngeal pain, tachypnoea, bronchospasm, cough, dyspnea paroxysmal nocturnal, hypoxia, rales, wheezing</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea, diarrhea, vomiting</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Abdominal pain, abdominal pain upper, dry mouth, dyspepsia, stomach discomfort, abdominal distension, ascites, constipation, dysphagia, flatulence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td></tr><tr><td colspan="2"><p>Common:</p></td><td style="vertical-align:top"><p>Elevated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver &nbsp;&nbsp;&nbsp; values (alanine &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aminotransferase, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aspartate aminotranserase, blood alkaline phosphatase, bilirubin conjugated, blood bilirubin)</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>cholestasis, hepatomegaly, hyperbilirubinemia, jaundice, hepatic function abnormal, hepatotoxicity, liver disorder, gamma-glutamyltransferase increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Rash, pruritus, erythema, hyperhidrosis</p></td></tr><tr><td><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Erythema multiforme, rash macular, rash maculo-papular, rash pruritic, urticaria, dermatitis allergic, pruritus generalized, rash erythematous, rash generalized, rash morbilliform, skin lesion</p></td></tr><tr><td><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Toxic epidermal necrolysis and Stevens-Johnson syndrome (see section</p><p>4.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue and bone disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Back pain, pain in extremity, bone pain, muscular weakness, myalgia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Renal failure, renal failure acute</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pyrexia, chills, infusion-site pruritus</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pain, catheter site pain, fatigue, feeling cold, feeling hot, infusion site erythema, infusion site induration, infusion site pain, infusion site swelling, injection site phlebitis, edema peripheral, tenderness, chest discomfort, chest pain, face edema, feeling of body temperature change, induration, infusion site extravasation, infusion site irritation, infusion site phlebitis, infusion site rash, infusion site urticaria, injection site erythema, injection site edema, injection site pain, injection site swelling, malaise, edema</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blood potassium decreased, blood albumin decreased</p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blood creatinine increased, red blood cells urine positive, protein total decreased, protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium increased, blood pressure increased, blood uric acid decreased, blood urine present, breath sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased, international normalized ratio increased, urinary casts, white blood cells urine positive, and pH urine increased</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Pediatric Patients</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Eosinophil count increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Flushing, hypotension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Elevated liver enzyme levels (AST, ALT)<strong> </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:<strong> </strong></p></td><td style="vertical-align:top"><p>Fever<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Chills, catheter site pain<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations: </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Decreased potassium, hypomagnesaemia, increased glucose, decreased phosphorus, and increased phosphorus<strong> </strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Post-Marketing experience</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Hepatic dysfunction<strong> </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Swelling and peripheral edema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations: </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypercalcemia</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>c. Description of selected adverse reactions: </strong></p><p><strong>&nbsp;</strong></p><p><strong>Adult Patients </strong></p><p>In clinical studies, 1865 adult individuals received single or multiple doses of caspofungin. 564 febrile neutropenic patients (empirical therapy study), 382 patients with invasive candidiasis, 228 patients with invasive aspergillosis, 297 patients with localized <em>Candida</em> infections, and 394 individuals enrolled in Phase I studies. In the empirical therapy study patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation (including 39 allogeneic transplantations). In the studies involving patients with documented Candida infections, the majority of the patients with invasive <em>Candida</em> infections had serious underlying medical conditions (e.g., hematologic or other malignancy, recent major surgery, HIV) requiring multiple concomitant medications. Patients in the non-comparative <em>Aspergillus</em> study often had serious predisposing medical conditions (e.g., bone marrow or peripheral stem cell transplants, hematologic malignancy, solid tumors or organ transplants) requiring multiple concomitant medications.</p><p><strong>&nbsp;</strong></p><p><strong>Phlebitis and other local reactions&nbsp; </strong></p><p>Phlebitis was a commonly reported local injection-site adverse reaction in all patient populations. Other local reactions included erythema, pain/tenderness, itching, discharge, and a burning sensation.</p><p><strong>&nbsp;</strong></p><p><strong>Clinical and Laboratory Abnormalities </strong></p><p>Reported clinical and laboratory abnormalities among all adults treated with caspofungin (total 1780) were typically mild and rarely led to discontinuation.</p><p>Caspofungin has also been evaluated at 150 mg daily (for up to 51 days) in 100 adult patients. The study compared caspofungin at 50 mg daily (following a 70-mg loading dose on Day 1) versus 150 mg daily in the treatment of invasive candidiasis. In this group of patients, the safety of caspofungin at this higher dose appeared generally similar to patients receiving the 50-mg daily dose of caspofungin. The proportion of patients with a serious drug-related adverse reaction or a drugrelated adverse reaction leading to caspofungin discontinuation was comparable in the 2 treatment groups.</p><p><strong>&nbsp;</strong></p><p><strong>Pediatric Patients </strong></p><p>Data from 5 clinical studies completed in 171 pediatric patients suggest that the overall incidence of clinical adverse experiences (26.3%; 95% CI -19.9, 33.6) is not worse than reported for adults treated with caspofungin (43.1%; 95% CI -40.0, 46.2). However, pediatric patients probably have a different adverse event profile compared to adult patients. The most common drug-related clinical adverse experiences reported in pediatric patients treated with caspofungin were pyrexia (11.7%), rash (4.7%) and headache (2.9%).</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;</p><p>&bull;&nbsp; Fax: +966-11-205-7662&nbsp;</p><p>&bull;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.&nbsp;</p><p>&bull;&nbsp; Toll free phone: 8002490000&nbsp;</p><p>&bull;&nbsp; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>&bull;&nbsp; Website: www.sfda.gov.sa/npc&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvertent administration of up to 400 mg of caspofungin in one day has been reported. These occurrences did not result in clinically important adverse reactions. Caspofungin is not dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Antimycotics for systemic use&nbsp;</p><p><strong>ATC Code: </strong>J02AX04</p><p>&nbsp;</p><p>Mechanism of action</p><p>Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesized from a fermentation product of <em>Glarea lozoyensis</em>. Caspofungin acetate inhibits the synthesis of beta (1,3)D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)D-glucan is not present in mammalian cells.</p><p>Fungicidal activity with caspofungin has been demonstrated against <em>Candida</em> yeasts. Studies <em>in vitro</em> and <em>in vivo</em> demonstrate that exposure of <em>Aspergillus</em> to caspofungin results in lysis and death of hyphal apical tips and branch points where cell growth and division occur.</p><p>&nbsp;</p><p>Caspofungin has <em>in vitro</em> activity against <em>Aspergillus</em> species (<em>Aspergillus fumigatus</em> [N = 75], <em>Aspergillus flavus</em> [N = 111], <em>Aspergillus niger </em>[N = 31], <em>Aspergillus nidulans</em> [N = 8], <em>Aspergillus terreus</em> [N = 52], and <em>Aspergillus candidu</em>s [N = 3]). Caspofungin also has <em>in vitro</em> activity against <em>Candida</em> species (<em>Candida albicans </em>[N = 1,032], <em>Candida dubliniensis</em> [N = 100], <em>Candida glabrata</em> [N = 151], <em>Candida guilliermondii</em> [N = 67], <em>Candida kefyr</em> [N = 62], <em>Candida krusei</em> [N = 147], <em>Candida lipolytica</em> [N = 20], <em>Candida lusitaniae</em> [N = 80], <em>Candida parapsilosis</em> [N = 215], <em>Candida rugosa</em> [N = 1], and<em> Candida tropicalis </em>[N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine. Susceptibility testing was performed according to a modification of both the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards [NCCLS]) method M38-A2 (for <em>Aspergillus</em> species) and method M27-A3 (for <em>Candida</em> species). Standardised techniques for susceptibility testing have been established for yeasts by EUCAST. However, interpretive breakpoints for caspofungin have not been approved by EUCAST. Isolates of <em>Candida</em> with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin &gt;2 mg/L (4- to 30-fold MIC increases) have been reported using standardized MIC testing techniques approved by the CLSI). Similarly, <em>C. parapsilosis</em> isolates intermediate to anidulafungin and micafungin can be regarded intermediate to caspofungin. Isolates of Candida with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin &gt;2 mg/L (4to 30 fold MIC increases) have been reported using standardized MIC testing techniques approved by the CLSI). The mechanism of resistance identified was FKS1/FKS2 gene mutation. These cases have been associated with poor clinical outcomes. Development of <em>in vitro</em> resistance to caspofungin by <em>Aspergillus</em> species has been identified. In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed. The mechanism of resistance has not been established. The incidence of resistance to caspofungin by various clinical isolates of <em>Candida</em> and <em>Aspergillus</em> is rare.</p><p>&nbsp;</p><p>Clinical Efficacy:</p><p><em>Invasive Candidiasis in Adult Patients:</em> Two hundred thirty-nine patients were enrolled in an initial study to compare caspofungin and amphotericin B for the treatment of invasive candidiasis. Twenty-four patients had neutropenia. The most frequent diagnoses were bloodstream infections (candidemia) (77%, n=186) and <em>Candida</em> peritonitis (8%, n=19); patients with <em>Candida</em> endocarditis, osteomyelitis, or meningitis were excluded from this study. Caspofungin 50 mg once daily was administered following a 70 mg loading dose, while amphotericin B was administered at 0.6 to 0.7 mg/kg/day to non-neutropenic patients or 0.7 to 1.0 mg/kg/day to neutropenic patients. The mean duration of intravenous therapy was 11.9 days, with a range of 1 to 28 days. A favorable response required both symptom resolution and microbiological clearance of the <em>Candida</em> infection. Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favorable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73% [80/109]) and amphotericin B (62% [71/115]) [% difference 12.7 (95.6% CI -0.7, 26.0)]. Among patients with candidemia, favorable response rates at the end of IV study therapy were comparable for caspofungin (72% [66/92]) and amphotericin B (63% [59/94]) in the primary efficacy analysis (MITT analysis) [% difference 10.0 (95.0% CI -4.5, 24.5)]. Data in patients with non-blood sites of infection were more limited. Favorable response rates in neutropenic patients were 7/14 (50%) in the caspofungin group and 4/10 (40%) in the amphotericin B group. These limited data are supported by the outcome of the empirical therapy study.</p><p>&nbsp;</p><p>In a second study, patients with invasive candidiasis received daily doses of caspofungin at 50 mg/day (following a 70-mg loading dose on Day 1) or caspofungin at 150 mg/day (see section 4.8). In this study, the caspofungin dose was administered over 2 hours (instead of the routine 1-hour administration). The study excluded patients with suspected <em>Candida</em> endocarditis, meningitis, or osteomyelitis. As this was a primary therapy study, patients who were refractory to prior antifungal agents were also excluded. The number of neutropenic patients enrolled in this study was also limited (8.0%). Efficacy was a secondary endpoint in this study. Patients who met the entry criteria and received one or more doses of caspofungin study therapy were included in the efficacy analysis. The favorable overall response rates at the end of caspofungin therapy were similar in the 2 treatment groups: 72% (73/102) and 78% (74/95) for the caspofungin 50-mg and 150-mg treatment groups, respectively (difference 6.3% [95% CI -5.9, 18.4]).</p><p>&nbsp;</p><p><em>Invasive Aspergillosis in Adult Patients</em>: Sixty-nine adult patients (age 18-80) with invasive aspergillosis were enrolled in an open-label, non-comparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Patients had to be either refractory to (disease progression or failure to improve with other antifungal therapies given for at least 7 days) (84% of the enrolled patients) or intolerant of (16% of enrolled patients) other standard antifungal therapies. Most patients had underlying conditions (hematologic malignancy [N = 24], allogeneic bone marrow transplant or stem cell transplant [N = 18], organ transplant [N = 8], solid tumor [N = 3], or other conditions [N = 10]). Stringent definitions, modeled after the Mycoses Study Group Criteria, were used for diagnosis of invasive aspergillosis and for response to therapy (favorable response required clinically significant improvement in radiographs as well as in signs and symptoms). The mean duration of therapy was 33.7 days, with a range of 1 to 162 days. An independent expert panel determined that 41% (26/63) of patients receiving at least one dose of caspofungin had a favorable response. For those patients who received more than 7 days of therapy with caspofungin, 50% (26/52) had a favorable response. The favorable response rates for patients who were either refractory to or intolerant of previous therapies were 36% (19/53) and 70% (7/10), respectively. Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favorable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/5 versus 17/48, respectively). The response rates among patients with pulmonary disease and extrapulmonary disease were 47% (21/45) and 28% (5/18), respectively. Among patients with extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible CNS involvement had a favorable response.</p><p>&nbsp;</p><p><em>Empirical Therapy in Febrile, Neutropaenic Adult Patients</em>: A total of 1,111 patients with persistent fever and neutropenia were enrolled in a clinical study and treated with either caspofungin 50 mg once daily following a 70 mg loading dose or liposomal amphotericin B 3.0 mg/kg/day. Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropenia (&lt;500 cells/mm3 for 96 hours) and fever (&gt;38.0&deg;C) not responding to &ge; 96 hours of parenteral antibacterial therapy. Patients were to be treated until up to 72 hours after resolution of neutropenia, with a maximum duration of 28 days. However, patients found to have a documented fungal infection could be treated longer. If the drug was well tolerated but the patient&#39;s fever persisted and clinical condition deteriorated after 5 days of therapy, the dosage of study drug could be increased to 70 mg/day of caspofungin (13.3% of patients treated) or to 5.0 mg/kg/day of liposomal amphotericin B (14.3% of patients treated). There were 1,095 patients included in the primary Modified Intention-To-Treat (MITT) efficacy analysis of overall favorable response; caspofungin (33.9%) was as effective as liposomal amphotericin B (33.7%) [% difference 0.2 (95.2% CI &ndash;5.6, 6.0)]. An overall favorable response required meeting each of 5 criteria: (1) successful treatment of any baseline fungal infection (caspofungin 51.9% [14/27], liposomal amphotericin B 25.9% [7/27]), (2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment (caspofungin 94.8% [527/556], liposomal amphotericin B 95.5% [515/539]), (3) survival for 7 days after completion of study therapy (caspofungin 92.6% [515/556], liposomal amphotericin B 89.2% [481/539]), (4) no discontinuation from the study drug because of drug-related toxicity or lack of efficacy (caspofungin 89.7% [499/556], liposomal amphotericin B 85.5% [461/539]), and (5) resolution of fever during the period of neutropenia (caspofungin 41.2% [229/556], liposomal amphotericin B 41.4% [223/539]). Response rates to caspofungin and liposomal amphotericin B for baseline infections caused by <em>Aspergillus</em> species were, respectively, 41.7% (5/12) and 8.3% (1/12), and by <em>Candida </em>species were 66.7% (8/12) and 41.7% (5/12). Patients in the caspofungin group experienced breakthrough infections due to the following uncommon yeasts and molds: <em>Trichosporon </em>species (1), <em>Fusarium</em> species (1), <em>Mucor</em> species (1), and <em>Rhizopus</em> species (1).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Pediatric population </em></strong></p><p>The safety and efficacy of caspofungin was evaluated in pediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials. The study design, diagnostic criteria, and criteria for efficacy assessment were similar to the corresponding studies in adult patients (see section 5.1).</p><p>&nbsp;</p><p>The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, doubleblind study comparing caspofungin (50 mg/m<sup>2</sup> IV once daily following a 70-mg/m<sup>2</sup> loading dose on Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in pediatric patients with persistent fever and neutropenia. The overall success rates in the MITT analysis results, adjusted by risk strata, were as follows: 46.6% (26/56) for caspofungin and 32.2% (8/25) for liposomal amphotericin B.</p><p>&nbsp;</p><p>The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in pediatric patients (ages 6 months to 17 years) with invasive candidiasis, esophageal candidiasis, and invasive aspergillosis (as salvage therapy). Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis. Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis. The favorable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81% (30/37) in invasive candidiasis, 50% (5/10) in invasive aspergillosis, and 100% (1/1) in esophageal candidiasis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Caspofungin acetate is administered intravenously, the absorption is not applicable.</p><p>&nbsp;</p><p>Distribution</p><p>Caspofungin is extensively bound to albumin. The unbound fraction of caspofungin in plasma varies from 3.5% in healthy volunteers to 7.6% in patients with invasive candidiasis. Distribution plays the prominent role in caspofungin plasma pharmacokinetics and is the rate-controlling step in both the alpha- and beta-disposition phases. The distribution into tissues peaked at 1.5 to 2 days after dosing when 92% of the dose was distributed into tissues. It is likely that only a small fraction of the caspofungin taken up into tissues later returns to plasma as parent compound. Therefore, elimination occurs in the absence of a distribution equilibrium, and a true estimate of the volume of distribution of caspofungin is currently impossible to obtain.</p><p>&nbsp;</p><p>Biotransformation</p><p>Caspofungin undergoes spontaneous degradation to an open ring compound. Further metabolism involves peptide hydrolysis and N-acetylation. Two intermediate products, formed during the degradation of caspofungin to this open ring compound, form covalent adducts to plasma proteins resulting in a low-level, irreversible binding to plasma proteins.</p><p>&nbsp;</p><p><em>In vitro</em> studies show that caspofungin is not an inhibitor of cytochrome P450 enzymes 1A2, 2A6, 2C9, 2C19, 2D6 or 3A4. In clinical studies, caspofungin did not induce or inhibit the CYP3A4 metabolism of other medicinal products. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.</p><p>&nbsp;</p><p>Elimination</p><p>The elimination of caspofungin from plasma is slow with a clearance of 10-12 ml/min. Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour intravenous infusions. A short alpha-phase occurs immediately post-infusion, followed by a beta-phase with a half-life of 9 to 11 hours. An additional gamma-phase also occurs with a half-life of 45 hours. Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance.</p><p>&nbsp;</p><p>Approximately 75% of a radioactive dose was recovered during 27 days: 41% in urine and 34% in feces. There is little excretion or biotransformation of caspofungin during the first 30 hours after administration. Excretion is slow and the terminal half-life of radioactivity was 12 to 15 days. A small amount of caspofungin is excreted unchanged in urine (approximately 1.4% of dose).</p><p>&nbsp;</p><p>Caspofungin displays moderate non-linear pharmacokinetics with increased accumulation as the dose is increased, and a dose dependency in the time to reach steady state upon multiple-dose administration.</p><p>&nbsp;</p><p>Characteristics in patients&nbsp;</p><p>Increased caspofungin exposure was seen in adult patients with renal impairment and mild liver impairment, in female subjects, and in the elderly. Generally the increase was modest and not large enough to warrant dosage adjustment. In adult patients with moderate liver impairment or in higher weight patients, a dosage adjustment may be necessary (see below).</p><p>&nbsp;</p><p>Weight: Weight was found to influence caspofungin pharmacokinetics in the population pharmacokinetic analysis in adult candidiasis patients. The plasma concentrations decrease with increasing weight. The average exposure in an adult patient weighing 80 kg was predicted to be about 23% lower than in an adult patient weighing 60 kg (see section 4.2).</p><p>&nbsp;</p><p>Renal impairment&nbsp;</p><p>Caspofungin pharmacokinetics were similar in adult volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and control subjects. Moderate (creatinine clearance 31 to 49 ml/min), advanced (creatinine clearance 5 to 30 ml/min), and end-stage (creatinine clearance &lt;10 ml/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49% for AUC). However, in adult patients with invasive candidiasis, esophageal candidiasis, or invasive aspergillosis who received multiple daily doses of caspofungin 50 mg, there was no significant effect of mild to advanced renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment. Caspofungin is not dialyzable, thus supplementary dosing is not required following hemodialysis.</p><p>&nbsp;</p><p>Hepatic impairment</p><p>In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20 and 75%, respectively. There is no clinical experience in adult patients with severe hepatic impairment and in pediatric patients with any degree of hepatic impairment. In a multiple-dose study, a dose reduction of the daily dose to 35 mg in adult patients with moderate hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen (see section 4.2).</p><p>&nbsp;</p><p><u>Gender</u></p><p>Caspofungin plasma concentrations were on average 17-38% higher in women than in men.</p><p>&nbsp;</p><p>Geriatric patients</p><p>A modest increase in AUC (28%) and C<sub>24h</sub> (32%) was observed in elderly male subjects compared with young male subjects. In patients who were treated empirically or who had invasive candidiasis, a similar modest effect of age was seen in older patients relative to younger patients.</p><p>&nbsp;</p><p>Pediatric Patients</p><p>In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg daily, the caspofungin plasma AUC<sub>0-24hr</sub> was generally comparable to that seen in adults receiving caspofungin at 50 mg daily. All adolescents received doses &gt;50 mg daily, and, in fact, 6 of 8 received the maximum dose of 70 mg/day. The caspofungin plasma concentrations in these adolescents were reduced relative to adults receiving 70 mg daily, the dose most often administered to adolescents.</p><p>&nbsp;</p><p>In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m<sup>2</sup> daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub> after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day.</p><p>In young children and toddlers (ages 12 to 23 months) receiving caspofungin at 50 mg/m<sup>2</sup> daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub> after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily and to that in older children (2 to 11 years of age) receiving the 50 mg/m<sup>2</sup> daily dose.</p><p>&nbsp;</p><p>Overall, the available pharmacokinetic, efficacy, and safety data are limited in patients 3 to 10 months of age. Pharmacokinetic data from one 10-month old child receiving the 50 mg/m<sup>2</sup> daily dose indicated an AUC<sub>0-24hr</sub> within the same range as that observed in older children and adults at the 50 mg/m<sup>2</sup> and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m<sup>2</sup> dose, the AUC<sub>0-24hr</sub> was somewhat higher.</p><p>In neonates and infants (&lt;3 months) receiving caspofungin at 25 mg/m<sup>2</sup> daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C<sub>1 hr</sub>) and caspofungin trough concentration (C<sub>24 hr</sub>) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily. On Day 1, C<sub>1 hr</sub> was comparable and C<sub>24 hr</sub> modestly elevated (36%) in these neonates and infants relative to adults. However, variability was seen in both C<sub>1 hr</sub> (Day 4 geometric mean 11.73 &micro;g/ml, range 2.63 to 22.05 &micro;g/ml) and C<sub>24 hr</sub> (Day 4 geometric mean 3.55 &micro;g/ml, range 0.13 to 7.17 &micro;g/ml). AUC<sub>0-24hr</sub> measurements were not performed in this study due to the sparse plasma sampling. Of note, the efficacy and safety of caspofungin have not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age.</p><p>&nbsp;</p><p>Race&nbsp;</p><p>Patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and Mestizos.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated dose toxicity studies in rats and monkeys using doses up to 7-8 mg/kg given intravenously showed injection site reactions in rats and monkeys, signs of histamine release in rats, and evidence of adverse effects directed at the liver in monkeys. Developmental toxicity studies in rats showed that caspofungin caused decreases in fetal body weights and an increase in the incidence of incomplete ossification of vertebra, sternebra, and skull bone at doses of 5 mg/kg that were coupled to adverse maternal effects such as signs of histamine release in pregnant rats. An increase in the incidence of cervical ribs was also noted. Caspofungin was negative in <em>in vitro</em> assays for potential genotoxicity as well as in the <em>in vivo</em> mouse bone marrow chromosomal test. No long-term studies in animals have been performed to evaluate the carcinogenic potential. For caspofungin, there were no effects on fertility in studies conducted in male and female rats up to 5 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Mannitol</p><p>Succinic acid</p><p>Sodium hydroxide (to adjust the pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not mix or co-infuse AFUNDAS-L with any other medicines, as there are no data available on the compatibility of AFUNDAS-L with other intravenous substances, additives, or medicinal products. DO NOT USE ANY DILUENTS CONTAINING DEXTROSE (&alpha;-D-GLUCOSE), as AFUNDAS-L IS NOT STABLE IN DILUENTS CONTAINING GLUCOSE.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 
 
Reconstituted concentrate: should be used immediately. Stability data have shown that the concentrate for solution for infusion can be stored for up to 24 hours when the vial is stored at 25°C or less and reconstituted with water for injection. 
 
Diluted patient infusion solution: should be used immediately. Stability data have shown that the product can be used within 24 hours when stored at 25°C or less, or within 48 hours when the intravenous infusion bag (bottle) is stored refrigerated (2 to 8°C) and diluted with sodium chloride solution 9 mg/ml (0.9 %), 4.5 mg/ml (0.45 %), or 2.25 mg/ml (0.225 %) for infusion, or lactated Ringer's solution. 
 
AFUNDAS-L contains no preservatives. From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution and dilution have taken place in controlled validated aseptic conditions. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unopened Vials</u></p><p>Lyophilized vials should be stored in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In box; Type I, colorless glass vial with bromobutyl gray rubber stopper and transparent plasticaluminum seal, flip off cap, supplied in packs of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reconstitution of AFUNDAS-L</u></p><p>DO NOT USE ANY DILUENTS CONTAINING GLUCOSE, as caspofungin is not stable in diluents containing glucose. DO NOT MIX OR CO-INFUSE caspofungin WITH ANY OTHER MEDICINES, as there are no data available on the compatibility of caspofungin with other intravenous substances, additives, or medicinal products. Visually inspect the infusion solution for particulate matter or discolouration.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong><u>AFUNDAS-L 50 mg powder for concentrate for solution for infusion</u> </strong></p><p>INSTRUCTIONS FOR USE IN ADULT PATIENTS</p><p>Step 1 Reconstitution of conventional vials</p><p>To reconstitute the powder bring the vial to room temperature and aseptically add 10.5 ml of water for injection. The concentrations of the reconstituted vials will be 5.2 mg/ml.</p><p>&nbsp;</p><p>The white to off-white compact lyophilised powder will dissolve completely. Mix gently until a clear, colorless to slightly yellow solution is obtained. Reconstituted solutions should be visually inspected for particulate matter or discolouration. This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.</p><p>&nbsp;</p><p>Step 2 Addition of reconstituted AFUNDAS-L to patient infusion solution</p><p>Diluents for the final solution for infusion are: sodium chloride solution for injection or lactated Ringer&rsquo;s solution. The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate (as shown in the table below) to a 250 ml infusion bag or bottle. Reduced volume infusions in 100 ml may be used, when medically necessary, for 50 mg or 35 mg daily doses. Do not use if the solution is cloudy or has precipitated.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS</p><table border="0" cellspacing="0" cellpadding="0" style="width:650px"><tbody><tr><td style="vertical-align:top"><p><strong>DOSE* </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Volume of </strong></p></td><td style="vertical-align:top"><p><strong>Standard preparation </strong></p></td><td style="vertical-align:top"><p><strong>Reduced volume </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>reconstituted </strong></p><p><strong>AFUNDAS-L for </strong></p><p><strong>transfer to intravenous bag or bottle</strong></p></td><td style="vertical-align:top"><p>(reconstituted</p><p>AFUNDAS-L added to</p><p>250 ml) final concentration&nbsp;</p></td><td style="vertical-align:top"><p><strong>infusion </strong>(reconstituted</p><p>AFUNDAS-L added</p><p>to 100 ml) final concentration&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>0.20 mg/ml</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>50 mg at reduced volume</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.47 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>35 mg for moderate hepatic impairment (from one 50 mg vial)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7 ml</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.14 mg/ml</p></td><td style="vertical-align:top"><p>&nbsp;-</p></td></tr><tr><td style="vertical-align:top"><p>35 mg for moderate hepatic impairment (from one 50 mg</p><p>vial) at reduced volume</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7 ml</p></td><td style="vertical-align:top"><p>&nbsp;-</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.34 mg/ml</p></td></tr></tbody></table><p>* 10.5 ml should be used for reconstitution of all vials</p><p>&nbsp;</p><p>INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS</p><p><em><u>Calculation of Body Surface Area (BSA) for paediatric dosing</u> </em></p><p>Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller Formula)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BSA (m<sup>2</sup>) = <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_32484" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:107.4pt;height:25.2pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/14118/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="143" height="34" src="file:///C:/Users/14118/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /> &nbsp;</p><p>&nbsp;</p><p><strong><em><u>Preparation of the 70 mg/m</u><sup>2</sup><u> infusion for paediatric patients &gt;3 months of age (using a 50-mg</u> <u>vial)</u> </em></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Determine the actual loading dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 70 mg/m<sup>2</sup> = Loading Dose</p><p>The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Equilibrate the refrigerated vial of AFUNDAS-L to room temperature.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Aseptically add 10.5 ml of water for injection.<sup>a</sup> This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup> This will give a final caspofungin concentration in the vial of 5.2 mg/ml (if using a 50-mg vial).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Remove the volume of medicine equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup> of reconstituted AFUNDAS-L to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>c</sup> of reconstituted AFUNDAS-L can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p>&nbsp;</p><p><strong><em><u>Preparation of the 50 mg/m</u><sup>2</sup><u> infusion for paediatric patients &gt;3 months of age (using a 50-mg</u> <u>vial)</u> </em></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 50 mg/m<sup>2</sup> = Daily Maintenance Dose&nbsp;</p><p>The daily maintenance dose should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Equilibrate the refrigerated vial of AFUNDAS-L to room temperature.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Aseptically add 10.5 ml of water for injection.<sup>a</sup> This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup> This will give a final caspofungin concentration in the vial of 5.2 mg/ml.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Remove the volume of medicine equal to the calculated daily maintenance dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup> of reconstituted AFUNDAS-L to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>c</sup> of reconstituted AFUNDAS-L can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p><strong><em>Preparation notes: </em></strong></p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The white to off-white cake will dissolve completely. Mix gently until a clear, colorless to slightly yellow solution is obtained.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AFUNDAS-L is formulated to provide the full labeled vial dose (50 mg) when 10 ml is withdrawn from the vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gensenta İlaç Sanayi ve Ticaret A.Ş.  İş Kuleleri, Levent Mah., Meltem Sok.  No: 10 Kule: 2 Kat: 24  4. Levent, Beşiktaş, İstanbul/TURKEY  Tel: +90 212 337 38 00  Fax: +90 212 337 38 01  
e-mail: info@gensenta.com.tr 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>